迪皮里丁受体突变会导致低血压周期性
L J Ptácek1, R Tawil, R C Griggs
1Department of Neurology, University of Utah Health Sciences Center, Salt Lake City 84132.
Cell
|June 17, 1994
概括
低血压周期性 (hypoKPP) 与二皮里丁 (DHP) 受体基因的突变有关. 这些遗传变化导致偶尔的肌肉衰弱和低血清水平.
科学领域:
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
- 神经学 神经学
背景情况:
- 低血压周期性 (hypoKPP) 是一种遗传性肌肉疾病.
- 它会导致与低水平相关的肌肉衰弱发作.
- 之前的研究将hypoKPP与位于二皮里丁 (DHP) 受体基因附近的染色体1联系起来.
研究的目的:
- 为了确定负责低血压周期性 (hypoKPP) 的特定基因.
- 描述与hypoKPP相关联的二二胺 (DHP) 受体基因内的突变.
主要方法:
- 基因链接分析以定位hypoKPP基因.
- 在dihydropyridine (DHP) 受体基因中患者特异突变的表征.
- 分析突变部位和预测的氨基酸替代.
主要成果:
- 在33个hypoKPP亲属中的11个中确定了二二胺 (DHP) 受体基因的患者特异性突变.
- 突变发生在特定的核酸位置,改变了保存的氨酸残留物.
- 一个突变被确定为家族病例中的de novo.
结论:
- 二皮里丁 (DHP) 受体基因被确认为低血压周期性 (hypoKPP) 的致病基因.
- 这一发现为hypoKPP和潜在的治疗点提供了分子基础.
- 目前已知没有其他人类疾病是由于二二氨酸 (DHP) 受体突变造成的.
相关概念视频
Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
Diabetic Ketoacidosis ll: Pathophysiology
Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...


